Kala Bio Inc. (NASDAQ:KALA) on Monday said it has commercially launched its first enterprise AI product, delivering on a two-week timeline.
CEO Avi Minkowitz said the rollout of the Bionic Intelligence Research Agent (BIRA) demonstrates the company’s execution capabilities and its intent to scale commercial AI offerings through its Researgency.ai platform, under exclusive worldwide license with Younet AI.
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
Minkowitz emphasized that the product is already operational rather than a prototype.
Kala Bio AI Agent Built For Biotech And Pharma Research
BIRA is designed as a fully autonomous research specialist tailored for biotechnology and pharmaceutical workflows.
Powered by a 70-billion-parameter language model, the agent processes complex research queries by synthesizing data from scientific literature, clinical trial registries, patent databases, and industry intelligence sources.
Its deployment within VPN-secured, client-owned infrastructure serves as a key differentiator, ensuring that proprietary research data remains fully contained without external exposure.
Focus On Data Integrity, Compliance And Insights
The platform integrates multiple features aimed at enterprise-grade research reliability.
These include automated verification of sources, confidence scoring of outputs, and identification of data gaps or inconsistencies. Results are presented through interactive visualizations designed to support R&D decision-making.
Additionally, pre-built connectors allow seamless access to a wide range of scientific, regulatory, and business datasets through a single secure interface.
Pipeline Expansion Targets Real-Time Intelligence Tools
Kala and Younet are advancing four near-term capabilities to expand the platform’s functionality.
These include automated daily research summaries, real-time event alerts for clinical and regulatory developments, continuous patent monitoring, and tools to identify overlooked or expired intellectual property with redevelopment potential.
Together, these modules aim to enhance competitive intelligence and streamline research workflows across therapeutic areas.
Seeks To Build Palantir For Biotech
Kala Bio in March said it is building the Palantir for biotech.
Just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry.
KALA Stock Price Activity: Kala Bio shares were up 5.24% at $0.18 during premarket trading on Monday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments